CLOSED STUDIES / Cervical Cancer

GEICO 2005/01


Phase II exploratory study to evaluate the efficacy and safety of weekly topotecan in the treatment of persistent or relapsing cervical cancer after failure of first-line treatment with platinum derivatives.

GEICO Coordinator

Dr. María Jesús Rubio

Patients Recruited

34 patients

Inclusion Closing Date

March 2007


“Phase II study of weekly Topotecan in recurrent of metastatic cervical cancer: a Geico Study” M.J. Rubio, A. Santaballa, Y. García, A. González, I. Bover, E. Calvo, J.A. Contreras, J.M. Del Campo, A. de Juan, A. Poveda. Journal Clinical Of Oncology 26: 2008 (May 20 suppl.:abst.5591).